Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial

Ogbuagu, Onyema, Molina, Jean-Michel, Chetchotisakd, Ploenchan · Clinical Infectious Diseases · 2025